Evaxion AS SEC Filings

Evaxion A/S reported a leadership change via a Form 6-K. On October 27, 2025, the company issued a press release titled “Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer,” furnished as Exhibit 99.1.

The report is also incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-1, and F-3, ensuring the press release becomes part of those filings. The submission was signed by Interim Chief Executive Officer Birgitte Rønø.

Evaxion A/S reported share sales and warrant exercises that increased its share capital and updated its Articles of Association. On September 25, 2025, the company sold 1,018,000 American Depositary Shares in an at-the-market offering at an average price of $4.3931 per ADS, generating approximately $4.3 million in proceeds after fees. The related capital increase of nominal DKK 12,725,000 became effective on September 26, 2025, bringing total share capital to nominal DKK 91,682,151.50.

From October 3 to October 10, 2025, warrant exercises led to additional registered share capital increases totaling nominal DKK 7,366,312.5, resulting in aggregate share capital of nominal DKK 99,048,464. These exercises brought in aggregate cash consideration of DKK 10,344,064.35 (approximately USD 1,608,519). The Articles of Association were amended on the relevant dates to reflect these changes and are provided as Exhibit 1.1.

Evaxion A/S furnished a Form 6-K announcing a press release titled “Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01.” The press release, dated October 17, 2025, is provided as Exhibit 99.1.

The report states this Form 6-K is incorporated by reference into Evaxion’s effective registration statements, including Forms S-8, F-3, and F-1. The filing highlights the reported 75% objective response rate for EVX-01 as described in the press release title.

Evaxion A/S furnished a Form 6-K noting it issued a press release about presenting data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025. The press release, dated October 13, 2025, is included as Exhibit 99.1.

The report is also incorporated by reference into Evaxion’s existing U.S. registration statements on Forms S-8, F-3, and F-1. This filing primarily provides disclosure of the upcoming scientific presentation and ensures the press release forms part of the company’s registered offering documents.

Evaxion A/S filed a Form 6-K furnishing a press release dated October 8, 2025 that announces the company has expanded its AI-Immunology™ platform by adding an automated vaccine design module. The filing states the press release is provided as Exhibit 99.1 and that this Form 6-K is incorporated by reference into several of the company's registration statements, to the extent not superseded by later filings. No financial metrics, commercialization milestones, timeline, or technical performance data for the new module are included in the filing.

Evaxion A/S disclosed that it will present new biomarker data for its AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting. The Form 6-K furnishes a press release as Exhibit 99.1 and incorporates this report by reference into several of the company’s registration statements. The filing contains no financial results, trial endpoints, patient counts, or detailed data—only the announcement of the planned presentation. Investors are informed of the forthcoming scientific disclosure but must look to the press release or the SITC presentation itself for substantive clinical or biomarker findings.

Evaxion A/S furnished a press release dated September 25, 2025 announcing that it has out-licensed its vaccine candidate EVX-B3 to MSD. The Form 6-K states the press release is filed as Exhibit 99.1 and that this report is incorporated by reference into several of Evaxion's registration statements, including Forms S-8, F-3 and multiple F-1 filings. The filing provides notice of the transaction but includes no financial terms, milestone schedules, or operational details within this report.

Evaxion A/S furnished a Form 6-K reporting that it issued a press release titled "Evaxion to present at several conferences during the second half of 2025" and furnished that press release as Exhibit 99.1 to the report. The company states this Form 6-K is incorporated by reference into multiple registration statements, including Forms S-8, F-3 and several Form F-1 filings, such that the press release and related disclosure become part of those registration statements to the extent not superseded. The report is signed on behalf of the registrant by Birgitte Rønø, Interim Chief Executive Officer.